Can immune checkpoint inhibitors be safely given in a patient with chronic GVHD?
E.g., for treatment of a secondary malignancy. Do the organs involved and the degree of severity influence your decision-making?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Memorial Sloan Kettering Cancer Center
Answered on
If the patient has active chronic GVHD the risk-benefit ratio of immune checkpoint blockade needs to be carefully assessed since there are well documented instances of severe GVHD flairs or immune-related adverse effects - in a patient on chronic immune suppression and quiescent GVHD we recommend no...
Join for free or sign in to see the full answer